Prognosis to Radiation Unlocked: How Hypoxia Methylome may hold the Key in HNSCC.

Hypoxia in head and neck tumors has proven to be predictive of outcomes. Current hypoxia signatures have failed for patient treatment selection. In a recent study, the authors identified a hypoxia methylation signature as a more robust biomarker in HNSCC and shed light into the mechanism of hypoxia-mediated treatment resistance.